论文部分内容阅读
目的:评估复发性胶质母细胞瘤患者采用尼莫斯汀联合顺铂持续灌注化疗的应用前景。方法:回顾性分析2014年5月到2015年11月间复发性胶质母细胞瘤的补救性化疗病例,分为尼莫斯汀(CDDP)联合顺铂(ACNU)组和替莫唑胺(TMZ)组,评估两组近期疗效、生存率及不良反应的差异性。结果:联合组缓解率为52.6%,单药组缓解率为7.2%,联合组远期疗效高于单药组(P<0.05);联合组一年生存率为26.3%,单药组为23.3%,两组生存率对比无统计学意义(P<0.05);单药组不良反应发生情况低于联合组(P<0.05)。结论:复发性胶质母细胞瘤患者采用尼莫斯汀联合顺铂持续灌注化疗可提高生存率和缓解率,但骨髓抑制情况严重。
PURPOSE: To evaluate the potential of nevostatin plus cisplatin for continuous perfusion chemotherapy in patients with recurrent glioblastoma. Methods: Retrospective analysis of recurrent glioblastoma recapitulative chemotherapy cases between May 2014 and November 2015 were divided into three groups: nimostone (CDDP) plus cisplatin (ACNU) and temozolomide (TMZ) , To evaluate the short-term efficacy of the two groups, the survival rate and adverse reactions. Results: The remission rate was 52.6% in the combination group and 7.2% in the single drug group. The long-term curative effect in the combination group was higher than that in the single drug group (P <0.05). The one-year survival rate was 26.3% in the combination group and 23.3 in the single drug group % Respectively. There was no significant difference in survival rate between the two groups (P <0.05). The incidence of adverse reactions in the single drug group was lower than that in the combined group (P <0.05). CONCLUSION: Sustained perfusion chemotherapy with nimostine plus cisplatin improves survival and response rates in patients with recurrent glioblastoma, but bone marrow suppression is severe.